Pretreatment for 72 hours with a potent and selective FTO inhibitor, FB23-2 (30), reduced glutamine uptake and conversion to m + 5 glutamate in ccRCC cells (Fig. 1, B and C). This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.